Pardoprunox
Alternative Names: SLV-308; SME-308Latest Information Update: 10 Apr 2017
Price :
$50 *
At a glance
- Originator Solvay
- Class Antidepressants; Antiparkinsonians; Anxiolytics; Benzoxazoles; Piperazines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Dopamine D3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Drug-induced dyskinesia; Parkinson's disease
Most Recent Events
- 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott
- 11 Jun 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 13th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2009)
- 19 Apr 2008 Efficacy and safety data from a phase II trial in Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)